Boomfish Wealth Group LLC Has $58,000 Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Boomfish Wealth Group LLC grew its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 17.1% during the third quarter, Holdings Channel.com reports. The firm owned 34,997 shares of the biopharmaceutical company’s stock after acquiring an additional 5,102 shares during the quarter. Boomfish Wealth Group LLC’s holdings in Esperion Therapeutics were worth $58,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Bellevue Group AG increased its stake in Esperion Therapeutics by 136.5% in the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock valued at $26,650,000 after buying an additional 5,739,800 shares during the last quarter. Wasatch Advisors LP increased its position in shares of Esperion Therapeutics by 2.7% in the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock valued at $24,467,000 after acquiring an additional 238,544 shares during the last quarter. Vanguard Group Inc. raised its holdings in Esperion Therapeutics by 71.8% during the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after acquiring an additional 3,688,796 shares in the last quarter. Marshall Wace LLP boosted its position in Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after purchasing an additional 2,087,635 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Esperion Therapeutics by 3,278.3% in the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after purchasing an additional 555,382 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ESPR shares. Needham & Company LLC dropped their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. StockNews.com raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Bank of America downgraded shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $2.90 to $2.50 in a research report on Thursday, June 20th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Trading Up 6.1 %

Shares of NASDAQ ESPR opened at $2.09 on Tuesday. The company has a market capitalization of $395.97 million, a P/E ratio of -2.11 and a beta of 1.00. Esperion Therapeutics, Inc. has a 12 month low of $0.71 and a 12 month high of $3.40. The stock has a 50 day moving average of $1.82 and a 200-day moving average of $2.17.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. Analysts predict that Esperion Therapeutics, Inc. will post -0.04 EPS for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.